Unraveling Lennox–Gastaut Syndrome: From Molecular Pathogenesis to Precision Diagnosis and Targeted Therapy Evolving Therapeutic Strategies
International Journal of Molecular Sciences · 30.01.2026 · 27 (3) · 1382
DOI: 10.3390/ijms27031382 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.01.2026. Verfasst von Ji-Hoon Na und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Republic of Korea. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lennox–Gastaut syndrome (LGS) is a rare and severe developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, mandatory tonic seizures, cognitive and behavioral impairment, and distinctive electroencephalographic features, including slow spike–wave discharges and generalized paroxysmal fast activity. Despite decades of therapeutic advances, LGS remains associated with profound lifelong disability and the absence of a single disease-defining molecular mechanism. Recent advances in genetics, neurophysiology, and network neuroscience have reframed LGS as a convergent network encephalopathy, in which diverse genetic, structural, metabolic, immune, and acquired insults funnel into shared molecular hubs, leading to thalamocortical network dysfunction. This framework helps explain the limited efficacy of purely syndrome-based treatments. This review synthesizes current evidence on electroclinical phenotyping, molecular and network pathogenesis, and contemporary diagnostic workflows and proposes a molecule-to-precision-therapy framework for LGS. We critically appraise pharmacologic, dietary, surgical, and neuromodulatory therapies, emphasizing drop seizures as a major driver of morbidity. Among available treatments, cannabidiol shows the most consistent and clinically meaningful efficacy for drop seizures, with benefits extending beyond seizure counts to seizure-free days and caregiver-relevant outcomes. Finally, we highlight key gaps and future directions, including etiology-stratified trials, network-guided interventions, and outcome measures that capture long-term developmental and quality-of-life impacts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Republic of Korea.
ORCID-Profile: Ji-Hoon Na, Young-Mock Lee
Zitieren
APA
Na, J. H., & Lee, Y. M. (2026). Unraveling Lennox–Gastaut Syndrome: From Molecular Pathogenesis to Precision Diagnosis and Targeted Therapy Evolving Therapeutic Strategies. International Journal of Molecular Sciences, 27(3), 1382. https://doi.org/10.3390/ijms27031382
Vancouver
Na JH, Lee YM. Unraveling Lennox–Gastaut Syndrome: From Molecular Pathogenesis to Precision Diagnosis and Targeted Therapy Evolving Therapeutic Strategies. International Journal of Molecular Sciences. 2026;27(3):1382. doi:10.3390/ijms27031382
BibTeX
@article{Na2026,
author = {Na, Ji-Hoon and Lee, Young-Mock},
title = {Unraveling Lennox–Gastaut Syndrome: From Molecular Pathogenesis to Precision Diagnosis and Targeted Therapy Evolving Therapeutic Strategies},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {3},
pages = {1382},
doi = {10.3390/ijms27031382}
}
EUVIMED